We develop broad-spectrum inhibitors of bacterial toxins that interfere with the intracellular trafficking machinery. As a result, these inhibitors have also antiviral, anti-intracellular bacteria and anti-parasitic activities. We also develop a fragment of the diphtheria toxin as an inhibitor of HB-EGF for the treatment of rapidly progressive glomerulonephritis, a rare kidney disease.

• Chemical modifications of proteins (Laurent Devel)

We developed original chemical and enzymatic strategies for the site-selective modification of proteins in vitro and in vivo. By relying on these approaches, we design new chemical tools such as protein-drug conjugates and chemical probes with potential diagnostic and therapeutic applications in various pathologies including cancer, inflammation and neurodegenerative diseases.

• Immunogenicity and Engineering of antibodies (Hervé Nozach)

The team focuses its research on the mechanisms and early stage evaluation of immunogenicity of therapeutic proteins and antibodies and on the engineering of antibodies using Yeast Surface Display. Our main objective is to develop new antibody-related molecules with high affinity, controlled selectivity and low immunogenicity.

• Synthetic biology and Evolution (Oscar Pereira-Ramos)

Cells and biomolecules with new or improved function can  bear considerable socio-economic impact.  Our team is interested in using synthetic biology tools and concepts in order to have a deeper insight on biosystems, to create live machines and to obtain engineered molecules applied to research and health.

The laboratory (LPEM) research activity is based on the discovery, pharmacological characterization, engineering and in-vivo pre-clinical evaluation of natural peptides and phycotoxins to develop innovate drugs and efficient detection kits.  

• Discovery of imaging agents and drug candidates
  

• Peptide engineering 
  

• Pharmacological studies 
  

• In vivo proof of concept and biodistribution studies

• Detection of neurotoxins